Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

Undertaking a study of proteins found in the complement system, an important part of the immune system, of patients with long COVID, researchers have identified a blood protein ‘signature’ that may ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...